Adverse reactions to L-asparaginase in oncopediatric patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Vigilância Sanitária em Debate |
Texto Completo: | https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295 |
Resumo: | Introduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmacy Clinic service, in a philanthropic hospital, in Salvador, Bahia, Brazil. Method: This is a cross-sectional, retrospective, descriptive study, in which an analysis of nine electronic medical records of oncopediatic patients was performed using L-asparaginase from June 2017 to February 2018. Results: Among the patients, 66.7% were male and 55.6% were aged ≤ 5 years. Acute lymphoid leukemia was the diagnosis of all patients. 66.7% of the study group presented some type of adverse reaction, pruritus being the most frequent (36%) and in 66.7% of the situations, the drug was suspended. All reactions were reported. Conclusions: The results suggest that special attention is needed in oncopediatric patients, since the possibility of adverse drug reactions is higher. With the performance of the pharmacist in centers of high complexity in Oncology, it is possible to develop strategies and promote actions to prevent or minimize the occurrence of these adverse events during antineoplastic therapy. |
id |
FIOCRUZ-9_3485e2bca626eca853dc6f49d75b08ec |
---|---|
oai_identifier_str |
oai:ojs.visaemdebate.incqs.fiocruz.br:article/1295 |
network_acronym_str |
FIOCRUZ-9 |
network_name_str |
Vigilância Sanitária em Debate |
repository_id_str |
|
spelling |
Adverse reactions to L-asparaginase in oncopediatric patientsReações adversas ao medicamento L-asparaginase em pacientes oncopediátricosL-AsparaginaseLeuginaseOncopediatricsAcute Lymphoblastic LeukemiaPharmacovigilanceL-AsparaginaseLeuginaseOncopediátricosLeucemia Linfoblástica AgudaFarmacovigilânciaIntroduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmacy Clinic service, in a philanthropic hospital, in Salvador, Bahia, Brazil. Method: This is a cross-sectional, retrospective, descriptive study, in which an analysis of nine electronic medical records of oncopediatic patients was performed using L-asparaginase from June 2017 to February 2018. Results: Among the patients, 66.7% were male and 55.6% were aged ≤ 5 years. Acute lymphoid leukemia was the diagnosis of all patients. 66.7% of the study group presented some type of adverse reaction, pruritus being the most frequent (36%) and in 66.7% of the situations, the drug was suspended. All reactions were reported. Conclusions: The results suggest that special attention is needed in oncopediatric patients, since the possibility of adverse drug reactions is higher. With the performance of the pharmacist in centers of high complexity in Oncology, it is possible to develop strategies and promote actions to prevent or minimize the occurrence of these adverse events during antineoplastic therapy.Introdução: Reação adversa a medicamento (RAM) é definida como “qualquer resposta prejudicial ou indesejável e não intencional que ocorre com medicamentos em doses usualmente empregadas no ser humano. Objetivo: Descrever as reações adversas ao medicamento L-asparaginase, desenvolvidas por pacientes oncopediátricos, acompanhados pelo serviço de Farmácia Clínica, em um hospital filantrópico, de Salvador, Bahia, Brasil. Método: Trata-se de um estudo transversal, retrospectivo, descritivo, no qual foi realizada análise de nove prontuários eletrônicos dos pacientes oncopediátricos, em uso de L-asparaginase no período de junho de 2017 a fevereiro de 2018. Resultados: Entre os pacientes, 66,7% pertenciam ao sexo masculino e 55,6% apresentavam idade ≤ 5 anos. A Leucemia Linfoide Aguda foi o diagnóstico de todos os pacientes. Sessenta e sete vírgula sete por cento (66,7%) do grupo de estudo apresentou algum tipo de reação adversa, sendo prurido a mais frequente (36%) e, em 66,7% das situações, o medicamento foi suspenso. Todas as reações foram notificadas. Conclusões: Os resultados sugerem que é necessária uma atenção especial aos pacientes oncopediátricos, visto que a possibilidade de ocorrer reações adversas a medicamento é mais elevada. Com a atuação do farmacêutico nos centros de alta complexidade em oncologia, é possível desenvolver estratégias e promover ações para prevenir ou minimizar a ocorrência desses eventos adversos, durante a terapia antineoplásica.Instituto Nacional de Controle de Qualidade em Saúde2019-05-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed article""Artículo revisado por pares""Artigo avaliado pelos pares"application/pdfapplication/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/129510.22239/2317-269x.01295Health Surveillance under Debate: Society, Science & Technology ; Vol. 7 No. 2 (2019): May; 46-50Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 7 Núm. 2 (2019): Puede; 46-50Vigil Sanit Debate, Rio de Janeiro; v. 7 n. 2 (2019): Maio; 46-502317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1011https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1091Copyright (c) 2019 Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debatehttps://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessBarbosa, Khrisna FiuzaXavier, Rosa Malena FagundesRibeiro, Martamaria de Souza FerrazBendicho, Maria Teresita2023-06-27T15:11:12Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/1295Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T15:11:12Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.none.fl_str_mv |
Adverse reactions to L-asparaginase in oncopediatric patients Reações adversas ao medicamento L-asparaginase em pacientes oncopediátricos |
title |
Adverse reactions to L-asparaginase in oncopediatric patients |
spellingShingle |
Adverse reactions to L-asparaginase in oncopediatric patients Barbosa, Khrisna Fiuza L-Asparaginase Leuginase Oncopediatrics Acute Lymphoblastic Leukemia Pharmacovigilance L-Asparaginase Leuginase Oncopediátricos Leucemia Linfoblástica Aguda Farmacovigilância |
title_short |
Adverse reactions to L-asparaginase in oncopediatric patients |
title_full |
Adverse reactions to L-asparaginase in oncopediatric patients |
title_fullStr |
Adverse reactions to L-asparaginase in oncopediatric patients |
title_full_unstemmed |
Adverse reactions to L-asparaginase in oncopediatric patients |
title_sort |
Adverse reactions to L-asparaginase in oncopediatric patients |
author |
Barbosa, Khrisna Fiuza |
author_facet |
Barbosa, Khrisna Fiuza Xavier, Rosa Malena Fagundes Ribeiro, Martamaria de Souza Ferraz Bendicho, Maria Teresita |
author_role |
author |
author2 |
Xavier, Rosa Malena Fagundes Ribeiro, Martamaria de Souza Ferraz Bendicho, Maria Teresita |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Barbosa, Khrisna Fiuza Xavier, Rosa Malena Fagundes Ribeiro, Martamaria de Souza Ferraz Bendicho, Maria Teresita |
dc.subject.por.fl_str_mv |
L-Asparaginase Leuginase Oncopediatrics Acute Lymphoblastic Leukemia Pharmacovigilance L-Asparaginase Leuginase Oncopediátricos Leucemia Linfoblástica Aguda Farmacovigilância |
topic |
L-Asparaginase Leuginase Oncopediatrics Acute Lymphoblastic Leukemia Pharmacovigilance L-Asparaginase Leuginase Oncopediátricos Leucemia Linfoblástica Aguda Farmacovigilância |
description |
Introduction: Adverse drug reaction (ADR) is defined as “any harmful or undesirable and unintended response occurring with medicaments at doses usually employed in humans”. Objective: To describe the adverse reactions to L-asparaginase, developed by oncopediatric patients, accompanied by the Pharmacy Clinic service, in a philanthropic hospital, in Salvador, Bahia, Brazil. Method: This is a cross-sectional, retrospective, descriptive study, in which an analysis of nine electronic medical records of oncopediatic patients was performed using L-asparaginase from June 2017 to February 2018. Results: Among the patients, 66.7% were male and 55.6% were aged ≤ 5 years. Acute lymphoid leukemia was the diagnosis of all patients. 66.7% of the study group presented some type of adverse reaction, pruritus being the most frequent (36%) and in 66.7% of the situations, the drug was suspended. All reactions were reported. Conclusions: The results suggest that special attention is needed in oncopediatric patients, since the possibility of adverse drug reactions is higher. With the performance of the pharmacist in centers of high complexity in Oncology, it is possible to develop strategies and promote actions to prevent or minimize the occurrence of these adverse events during antineoplastic therapy. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-05-31 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion "Peer-reviewed article" "Artículo revisado por pares" "Artigo avaliado pelos pares" |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295 10.22239/2317-269x.01295 |
url |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295 |
identifier_str_mv |
10.22239/2317-269x.01295 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1011 https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1295/1091 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
dc.source.none.fl_str_mv |
Health Surveillance under Debate: Society, Science & Technology ; Vol. 7 No. 2 (2019): May; 46-50 Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 7 Núm. 2 (2019): Puede; 46-50 Vigil Sanit Debate, Rio de Janeiro; v. 7 n. 2 (2019): Maio; 46-50 2317-269X reponame:Vigilância Sanitária em Debate instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Vigilância Sanitária em Debate |
collection |
Vigilância Sanitária em Debate |
repository.name.fl_str_mv |
Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br |
_version_ |
1797042045369450496 |